Table 3.
Patient's and physician's survey
| Patient's s survey (n = 51) | |
|---|---|
| YES (%) | |
| Do the facilities seem to you decent, clean, and in accordance with the Clinical Genetic visit you have obtained? | 100.00% |
| The expert who has attended to you has taken the adequate time to explain to you all the necessary details in order to understand the scope of the Clinical Pharmacogenetic visit? | 100.00% |
| If studies were requested, have you understood what are they about, what it is expected from the result and how long it will take approximately? | 100.00% |
| Do you consider that the information was complete? | 100.00% |
| Regardless the number of experts assisting you in the visit, have you had enough privacy to comment with them the problems that afflict you? | 100.00% |
| IS (%) | |
|---|---|
| Transparency of the expert's information. | 89.57% |
| Time of response of the requested analysis with regard to your necessities. | 79.13% |
| Degree of confidence that you have in the results of the Clinical visit of this Institute. | 80.43% |
| Answer and/or possibility of new consultations if requested. | 83.48% |
| Telephone answering service of the administrative assistants when you call in order to make an appointment or clarify doubts. | 84.78% |
| GLOBAL IS | 83.47% |
| Physician's survey (n = 19) | |
|---|---|
| N (%) | |
| Service/Unit | |
| Internal Medicine | 4 (21.1) |
| Dermatology | 3 (15.8) |
| Pediatric nephrology (kidney transplantation) | 3 (15.8) |
| Gastroenterology | 2 (10.5) |
| Pediatric hemato‐oncology | 2 (10.5) |
| Psychiatry | 2 (10.5) |
| Oncology | 1 (5.3) |
| Clinical Immunology | 1 (5.3) |
| Thromboembolic unit | 1 (5.3) |
| Do you think that in the last 3 years have improved your understanding about the utility of pharmacogenetics in clinical practice? | |
| Yes | 19 (100) |
| If it has improved, which factors have contributed to it?* | |
| Contact with the Unit of Pharmacogenetics | 17 (89.5) |
| Development of protocol and guidelines | 4 (21.1) |
| Development of research projects related to pharmacogenetics | 11 (57.9) |
| Education, sessions or specific courses | 8 (42.1) |
| You make use of Pharmacogenetics according to:* | |
| Protocols agreed with the Unit of Pharmacogenetics | 8 (42.1) |
| Request of tests of individual cases | 14 (73.7) |
| In case of a recommendation of the Unit of Pharmacogenetics: | |
| I follow the indications reported by the Unit of Pharmacogenetics | 16 (84.2) |
| I do not follow the exact indications but I consider the genetic result | 3 (15.8) |
| I neither follow the indications nor I consider them | 0 (0) |
| IS (%) | |
|---|---|
| Do you consider appropriate the way of requesting a test and/or visit? | 79.0% |
| Do you consider appropriate the time of response? | 76.8% |
| Do you consider appropriate and useful the provided pharmacogenetic information? | 94.7% |
| Do you think that the use of pharmacogenetics has an impact on the management of your patient? | 85.3% |
| Do you think that in the following years the use of pharmacogenetics will increase in your specialty? | 91.6% |
| N (%) | |
|---|---|
| Which aspects do you think could increase the use of pharmacogenetics in your specialty?* | |
| Clearer guidelines about the use of pharmacogenetics | 11 (57.9) |
| Greater level of evidence about its clinical validity and utility | 11 (57.9) |
| Evaluation of the cost‐effectiveness of the use of pharmacogenetics | 10 (52.6) |
| Time of response more appropriate | 5 (26.3) |
IS: index of satisfaction.
*More than one choice question can be selected.